Proteus Biomedical's Raisin system
Proteus Digital Health, formerly known as Proteus Biomedical, has become the first company to receive Food and Drug Administration clearance for an ingestible biomedical sensor that monitors medication adherence.
The FDA granted 510(k) premarket approval to the Proteus Ingestible Event Marker (IEM) as a de novo medical device, meaning that there was no similar...
Last week German pharmaceutical company Boehringer Ingelheim announced a deal with Boston-based digital health company Healthrageous, which spun out of Partners Healthcare a few years ago. The companies plan to launch a pilot study to evaluate a lifestyle behavior modification program that aims to help people better manage type II diabetes.
The six-month study will leverage Healthrageous’...
In its quarterly investor call yesterday, Epocrates interim president and CEO Peter Brandt announced that the company has decided to back away from its EHR initiative to re-focus on its core products, namely pharma-supported, mobile clinical apps that physicians use at the point of care. Epocrates' physician user base stands at 340,000 users, according to the company. Brandt said the company "...
In recent months a number of deals, acquisitions, service and product launches have led to a growing discussion around the mobile health opportunities for pharma companies. There seem to be three big ones vying for the top.
Is it adding connectivity to clinical trials?
Earlier this month research analyst firm Cutting Edge Information (CEI) published a report that suggested pharma companies look...
At the end of September, Epocrates' worldwide user base for its mobile drug reference tools topped 1.4 million healthcare professionals, of which 340,000 are US physicians, according to a recent SEC filing. The company says that figure makes up more than 50 percent of all physicians in the US. For its interactive services business, Epocrates has had the 20 top pharmaceutical companies as clients...
London-based Exco InTouch, which is providing Pfizer with the mobile clinical trial technology its using in its REMOTE study, has secured about $4.67 million from Scottish Equity Partners (SEP). Exco plans to use the funds to expand and take advantage of the "significant growth opportunities" in the emerging mobile patient communication market, the company's press release stated.
Exco claims to...
Janet Woodcock, MD, Director, Center for Drug Evaluation and Research, FDA
Pfizer has announced the first FDA-approved clinical drug trial involving all-electronic home-based reporting, according to a report in the Wall Street Journal. The drug being "tested", Detrol, is intended for use by patients with overactive bladders. However, the real purpose of the study, according to Pfizer, is to...
Mobile marketing for healthcare not a strong opportunity yet: Pixels & Pills has a short and sweet interview with Manhattan Research's Monique Levy that is well worth a read: "The opportunity for healthcare marketers to leverage mobile marketing for patients in this time frame is comparatively less strong. As with PC-based access, patients predominantly use mobile devices to look for health...
